Zopiclone is a nonbenzodiazepine hypnotic agent used in the treatment of insomnia. More
Zopiclone is a nonbenzodiazepine hypnotic agent used in the treatment of insomnia.
Zopiclone-nonbenzodiazepine hypnotic agent
Zopiclone; Imovane; Amoban; Zimovane
Lyzop, Ziclone, Zolinox, Zolium, Zopicon, Zopitran
6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
Oral absorption, widely distributed with hepatic metabolism, excreted via feces and urine.
It is from the pyrazolopyrimidine class of non benzodiazepine hypnotic indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.
The recommended dose is 7.5 mg/day at bed time as PO.
For the short-term treatment of insomnia.
Metallic or bitter aftertaste; irritability, confusion, depressed mood, aggressiveness, incoordination, anterograde amnesia, mild increase in LFTs, drowsiness, lightheadedness, nausea, vomiting, urticaria, rashes.
Reduced hypnotic effect with phenytoin and carbamazepine. Increased drowsiness and incoordination with TCAs. Increased CNS depressant effect with alcohol and other CNS depressants. Decreased zopiclone concentration with rifampicin. Possible increase in zopiclone concentration with CYP3A4 inhibitors e.g. erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir.
Myasthenia gravis; respiratory failure; severe sleep apnoea syndrome; severe hepatic impairment; pregnancy, lactation.
Store in a dry place below 30°C.
388.808
C17H17ClN6O3
43200-80-2
Hepatic and renal insufficiency; elderly; psychiatric disorders; history of drug abuse. May impair ability to drive or operate machinery. Limit treatment duration to <4 weeks to minimise risk of dependence and tolerance. Avoid abrupt discontinuation of therapy.
